Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.

  • Northwest Biotherapeutics' Retained Earnings fell 634.31% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 634.31%. This contributed to the annual value of -$1.4 billion for FY2024, which is 616.14% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Retained Earnings stood at -$1.5 billion, which was down 634.31% from -$1.5 billion recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Retained Earnings registered a high of -$1.2 billion during Q4 2021, and its lowest value of -$1.5 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$1.4 billion (2023), whereas its average is -$1.4 billion.
  • The largest annual percentage gain for Northwest Biotherapeutics' Retained Earnings in the last 5 years was 1306.33% (2021), contrasted with its biggest fall of 6428.22% (2021).
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Retained Earnings stood at -$1.2 billion in 2021, then decreased by 8.81% to -$1.3 billion in 2022, then fell by 4.83% to -$1.4 billion in 2023, then dropped by 6.16% to -$1.4 billion in 2024, then fell by 4.26% to -$1.5 billion in 2025.
  • Its Retained Earnings was -$1.5 billion in Q3 2025, compared to -$1.5 billion in Q2 2025 and -$1.5 billion in Q1 2025.